Funding for this research was provided by:
National Institute for Health Research (NIHR) Health Technology Assessment (HTA) board (14/199/09)
Received: 13 December 2021
Accepted: 23 April 2022
First Online: 12 May 2022
: This study has been approved as part of the UK-REBOA trial by the Greater Manchester South Ethics Committee (17/NW/0352, IRAS project ID: 226135). Informed consent was obtained from all participants.
: We have obtained consent from all participants to publish anonymised quotes.
: JOJ is a consultant to CSL Behring and Cellphire Therapeutics. He has received study support from CSL Behring, RevMedX, and Infrascan. All other authors declare that they have no competing interests.